Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
Richardson PG et al. Lancet Haematol. 2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0. Epub 2015 Nov 16.

Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
Afifi S et al. Pharmacotherapy. 2015 Dec;35(12):1173-88. doi: 10.1002/phar.1671.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractorymultiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA et al. Lancet Oncol. 2015 Dec 3. pii: S1470-2045(15)00464-7. doi: 10.1016/S1470-2045(15)00464-7. [Epub ahead of print].

ENDEAVOR to change treatment for multiple myeloma?
Scheid C et al. Lancet Oncol. 2015 Dec 3. pii: S1470-2045(15)00531-8. doi: 10.1016/S1470-2045(15)00531-8. [Epub ahead of print].

Treatment with the HIV protease inhibitor Nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Driessen C et al. Haematologica. 2015 Dec 11. pii: haematol.2015.135780. [Epub ahead of print].

Panobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatment.
Richardson PG et al. Blood. 2015 Dec 2. pii: blood-2015-09-665018. [Epub ahead of print].

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
van de Donk NW et al. Blood. 2015 Dec 2. pii: blood-2015-10-646810. [Epub ahead of print].

Recent advances in the development of Aurora kinases inhibitors in hematological malignancies.
Choudary I et al. Ther Adv Hematol. 2015 Dec;6(6):282-94. doi: 10.1177/2040620715607415.

A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Ogawa Y et al. Int J Hematol. 2015 Nov 30. [Epub ahead of print].

Antibody based immunotherapy for multiple myeloma: it’s about time.
Sher T et al. Leuk Lymphoma. 2015 Dec 16:1-7. [Epub ahead of print].

Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.
Karp Leaf R et al. Curr Hematol Malig Rep. 2015 Dec;10(4):395-404. doi: 10.1007/s11899-015-0283-0.